This headline signals a significant upcoming data readout for BioVie's Long COVID treatment, Bezisterim. Positive results could lead to a substantial re-rating of BioVie's stock, while negative results would likely cause a sharp decline. The broader biotech sector, particularly companies developing Long COVID therapies, will be watching closely.
The completion of the last on-treatment visit in a Phase 2 trial is a critical milestone, indicating that the data collection phase is complete and analysis is underway. The expectation of topline results before the end of September 2026 sets a clear timeline for a major catalyst for BioVie. Positive results could validate their drug candidate, Bezisterim, for a significant unmet medical need (Long COVID), leading to a substantial increase in BIVI's valuation and potentially attracting partnership interest. Conversely, negative or inconclusive results would likely lead to a sharp sell-off. The biotech sector, especially those focused on post-viral syndromes and neurological disorders, will be impacted as this trial's outcome could influence research and development strategies.